Skip to main content
Premium Trial:

Request an Annual Quote

Correlogic and Matsui Renew Japanese Cancer Partnership

NEW YORK (GenomeWeb News) — Clinical proteomics company Correlogic Systems today said it has renewed a research collaboration and signed a new agreement with Japanese company Mitsui.
 
The new deal extends a relationship begun in 2004 when the companies signed an exploratory agreement to use Correlogic's pattern-recognition approach and technology to detect ovarian cancer in Japanese women. 
 
Correlogic said the new agreement marks the conclusion of that "mini-trial" and said the two companies will now continue to develop pattern-recognition tests for ovarian and other cancers that are prevalent in Japan.
 
Japanese pharmaceutical company Quintiles Japan will help the companies select samples and conduct more trials. 
 
Financial details of the new agreement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.